Complete Genetic Map of 34 Types of Cells in the Endosteum: Clues to Musculoskeletal Diseases Found in Vascular Endothelial Cells
Background
A Solid Barrier Hindering Precise Understanding of Skeletal Diseases
The endosteum, the inner surface of bone in contact with the bone marrow, is a dynamic region where bone remodeling constantly occurs. Many musculoskeletal diseases, including osteoporosis, originate from dysregulation in this area. However, due to the dense nature of bone tissue, there have been technical limitations in completely isolating and analyzing individual cells.
Previous studies have primarily focused on well-known cell populations, such as osteoblasts and osteoclasts. This approach fails to provide a comprehensive view of the complex cellular microenvironment within the endosteum. Consequently, identifying the specific cells in which disease-causing genes exert their effects has remained a long-standing challenge.
Key Findings
Gene Function Mechanisms Revealed by a Map of 34 Cell Types
An international research team, including Dr. Ryan C. Chai and Professor John P. Kemp from the Garvan Institute of Medical Research, collaborated to address this challenge using multi-scale analysis techniques. The researchers performed single-cell RNA sequencing (scRNA-seq) on the endosteal region of mice, identifying a total of 34 distinct cell types.
They then integrated the classified single-cell data with human bone mineral density (eBMD) genome-wide association study (GWAS) data and a database of rare skeletal disease genes. The resulting cell map was cross-validated by comparing it with a dataset of actual adult human bone tissue. Furthermore, the researchers compared the data with over 1,000 genetically modified mouse models to confirm the functional roles of the genes.
Vascular-Associated Cells: New Key Players in Bone Health
The most notable finding in this analysis is the identification of vascular-associated cells as a new cell population crucial for bone health. Traditional bone research has focused on osteoblasts and osteoclasts, but this study demonstrates that endothelial cells and vascular smooth muscle cells are closely involved in bone repair and maintenance.
In particular, the researchers elucidated a new role for plastin-3 (PLS3), a gene associated with rare genetic osteoporosis. In mouse and zebrafish models, blocking the function of the PLS3 gene resulted in noticeable thinning of blood vessels within the bone and inhibited angiogenesis. This suggests that vascular defects may be a major contributing factor to bone health deterioration, according to experts.
Significance and Prospects
A Precise Guide for Developing New Drugs for Musculoskeletal Diseases
This research is expected to serve as a precise compass for identifying and prioritizing therapeutic targets for musculoskeletal diseases. Previously, even when statistical associations between gene variants and diseases were identified, it was difficult to determine which specific cells should be targeted. This study provides a clear answer to this challenge.
The research team has made the extensive data accessible through a web platform (www.musculoskeletal-genomics.org) to allow researchers worldwide to query and search the data. However, some argue that there are limitations in directly applying the functional validation results obtained from mouse models to human physiology. To overcome the differences in the microenvironment between humans and animals, further studies involving multi-institutional clinical data and additional human-derived cell experiments are needed.
Nature Genetics, Published online: 10 July 2026; doi:10.1038/s41588-026-02640-9The study integrates cross-species single-cell and genomic analyses with functional validations to map the endosteal bone compartment, revealing musculoskeletal-disease-relevant cell types and transcriptional programs.
The endosteal gene map is a valuable resource that will significantly accelerate the discovery of new drug candidates for osteoporosis. In the development of new drug candidates, pharmaceutical companies can utilize the endosteal cell map to design drugs that specifically target vascular endothelial cells or osteoblasts, thereby preventing drug side effects. A specific example of a therapeutic development is the design of personalized gene therapies for children with osteoporosis caused by PLS3 gene mutations. By targeting specific endothelial cell receptors that induce blood vessel regeneration in the bone, drug screening to promote bone formation can be refined. Furthermore, based on multi-omics data related to bone density, personalized precision medicine services that predict individual bone loss risk in advance are expected to become more diverse.